Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Biotechnol Bioeng
; 119(1): 48-58, 2022 01.
Article
em En
| MEDLINE
| ID: mdl-34585736
ABSTRACT
Manufacturing has been the key factor limiting rollout of vaccination during the COVID-19 pandemic, requiring rapid development and large-scale implementation of novel manufacturing technologies. ChAdOx1 nCoV-19 (AZD1222, Vaxzevria) is an efficacious vaccine against SARS-CoV-2, based upon an adenovirus vector. We describe the development of a process for the production of this vaccine and others based upon the same platform, including novel features to facilitate very large-scale production. We discuss the process economics and the "distributed manufacturing" approach we have taken to provide the vaccine at globally-relevant scale and with international security of supply. Together, these approaches have enabled the largest viral vector manufacturing campaign to date, providing a substantial proportion of global COVID-19 vaccine supply at low cost.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Indústria Farmacêutica
/
Vacinas contra COVID-19
/
COVID-19
/
Desenvolvimento de Vacinas
/
ChAdOx1 nCoV-19
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Biotechnol Bioeng
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Reino Unido